Shanghai Yuesai Biotechnology

Unixell is an innovative pharmaceutical company specializing in the development of next-generation cell therapy drugs. The company leverages a robust technology platform that includes unique reprogramming technology, stem cell separation, high-precision genetic editing, and autonomous research and development for tracking the SASCR spectrum. Unixell primarily focuses on treating neurodegenerative diseases, rare diseases, and tumors. The company collaborates with healthcare institutions like Reginald Hospital to advance treatments such as Parkinson's auto stem cell therapy. Unixell operates in the biopharmaceutical market, serving healthcare providers and patients who require advanced therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary cell therapy drugs. Revenue is generated through partnerships, licensing agreements, and the sale of its therapeutic products.

Keywords: cell therapy, neurodegenerative diseases, rare diseases, tumors, genetic editing, stem cell technology, biopharmaceutical, reprogramming technology, SASCR spectrum, healthcare.